

An Anti-viral Activity in Moxibition Material, Magwort

Daisuke Sakamoto¹, Isao Horiuchi², Wenhan Wan³, Yoshihiko Kitada³, Nobuo Yamaguchi^{3*}, Shigeru Sakamoto¹, and Tamaki Takano¹

¹Department of Cardiovascular Disease, Faculty of Medicine, Kanazawa Medical University, Japan

²Seikaken, Co.Ltd, Isawa, Yamanashi, Japan

³Ishikawa Natural Medicinal Products Research Center, Foundation, Fukubatake, Kanazawa, Ishikawa Japan

*Corresponding author

Nobuo Yamaguchi, Ishikawa Natural Medicinal Products Research Center, Foundation, Fukubatake, Kanazawa, Ishikawa Japan

Submitted: 11 Jan 2022; Accepted: 17 Jan 2022; Published: 25 Jan 2022

Citation: Daisuke Sakamoto, Isao Horiuchi, Wenhan Wan, Yoshihiko Kitada and Nobuo Yamaguchi, et al. (2022). An Anti-viral Activity in Moxibition Material, Magwort. *J Agri Horti Res.*, 5(1): 01-05

Abstract

Background

A corona pandemic has been spread all over the world emerging some mutant's sub-strains. Many trials were reported including anti-viral agent and vaccines in many developing countries. However, none of the system still remained to be absolute for concur this evil corona virus. Therefore, we tried to review the traditional method for impel the way for this microorganism, especially suggesting traditional food additives. Coronavirus 2 (SARS-CoV-2) and has now spread to more than 200 countries and territories, infecting 222,097 persons at December 2021 and 2.059 daily death in us. The mugwort had been traditionally used as food additive as well as famous health care material, such in muxibution can reported as traditional health care in Eastern Asian countries. Our in vitro experiment also by the human cytomegalovirus (HCMV) of the DNA virus were suppressed for replication by this material.

Keywords: Anti-virus Agent, Corona Virus, Mugwort, Fermented herbs, FHD

Abbreviations:

FHD: fermented herbal decoction

HEL; human embryonic stem cell

Introduction

Mugwort (*Artemisia indica* Wild. var. *maximowiczii*) had been traditionally included in daily life of Japan. For mugwort had been succeeded to employ as medicinal plant in East Asian countries as food additive as well as health care substance, including heating therapy such as in moxybution. In Japan special rice cake that turn to β - to α -polysaccharide had been prepared artificially in early spring in order to featuring newly grown mugwort for traditional foods. For the people had been confirmed and including their annual life for health maintenance especially for infectious disease by the microorganism.

Materials and Methods

Human embryonic pulmonary fibroblast (HEL), obtained from human fetal lungs cultivated in 9.6 cm² shell until confluence with Dulbeccos Modified Eagle Medium (DMEM) medium was carried out, supplemented with 8% amount of fetal bovine serum (FCS). Towne strain of HCMV has been adsorbed and infected in a vari-

ety of infections (MOI) = 1 in HEL cells. After incubation at 37 °C for 1 hour, concentrations of 1, 3, 5% of mugwort was added and cultivated for 6 to 12 days, and anti-HCMV effects were quantified by the cytopathic effect under the microscope.

Results

Mugwort (*Artemisia indica* Willd. var. *maximowiczii*) are reported medicinal plant to improve health maintenance especially in East Asian countries at least in Japan.

Mugwort had been succeeded in East Asian countries as food additive as well as health care substance, including heating therapy famous for as in moxybution. In Japan special rice cake that turn to β - to α -polysaccharide had been prepared artificially in early spring in order to featuring newly grown mugwort for traditional foods.

Introduction

Novel coronavirus pneumonia (COVID-19) was first reported in Wuhan, China, in late December 2019 and has rapidly spread to more than dozens of countries, including the United States, with thousands of infected people and hundreds of deaths within a month. By February 25, 2021, more than 444 million cases had

been identified in the United States, and a total of 50 though and cases had been reported in Japan [1-4]. It is of great importance to look for fast and effective therapeutic drugs for COVID-19. Drug recycling is a common strategy in the search for antiviral treatment.

Network pharmacology is considered a promising approach to cost-effective drug development and has often been used to support the active ingredients of some Traditional Japanese medicine and its mechanisms of action [5-7]. It has transformed the research approach “one goal, one drug” into a strategy “network goal, multi-components”. Using the derivatives of mugwort, the targeting method for natural products was used based on the PubChem database, the targeting method is fast and could provide a relatively accurate result without the support of high-performance computing. Based on the principle of structural biology, molecular docking can be used to perform virtual drug screenings via a computer-aided drug molecular biology design. Therefore, molecular docking is an effective way to find and identify drug targets by filtering the docking energy and space between molecules and targets [8, 9]. The integration of molecular docking and network pharmacology is helpful to accelerate the progress of target determination and experimental verification. In this study, a technology-based strategy integrated with molecular docking was used to investigate the mechanism by which AHI COULD potentially improve COVID-19 to provide scientific evidence for clinical drugs [10].

Background and Invention

Objective

To date, we have found that Mugwort (main component is Artemisinin), one of the components contained in (Mugwort in Japan), the expression of the human cytomegalovirus (HCMV). Furthermore, since Mugwort is present in nature, no significant toxicity has been observed in ex vivo cell toxicity tests and toxicity tests in mouse in vivo.

Ganciclovir (GCV) currently used worldwide as an anti-HCMV drug has a strong specificity for HCMV infected cells and acts as a viral DNA synthesis inhibitor and exhibits strong anti-HCMV effects. However, as it is used over a long period of time, the pressure on medical expenditure and the appearance of viruses resistant to GCV is becoming a major social problem, and it is desirable to introduce new novel drugs with different mechanisms of action. Therefore, we looked for ingredients in herbal medicine and discovered Mugwort, which is more contained in Gramineae plants (we extract from Mugwort), and because of the study it showed antiviral effects.

Experimental Method for Anti-HCMV Action

Human embryonic pulmonary fibroblast (HEL), obtained from human fetal lungs cultivated in 9.6 cm² shell until confluence with Dulbeccos Modified Eagle Medium (DMEM) medium was carried out, supplemented with 8% amount of fetal bovine serum (FCS). Towne strain of HCMV has been adsorbed and infected in a variety of infections (MOI) = 1 in HEL cells. After incubation at 37 °C for 1 hour, concentrations of 1, 3, 5% of mugwort or novel compounds were added and cultivated for 6 to 12 days, and anti-HCMV effects were quantified by the cytopathic effect under the microscope.




Figure 1: Comparison of the antiviral effect of mugwort extracts, day 9th culture in vitro.

The antiviral activity against HCMV, mugwort, a novel compound, was investigated by cytopathic effects.

As a result, novel compound was suppressed the cytopathic effect by about 30% at 1% concentration and about 50% at 3% concentration (3 and 4 of Fig.1), and completely suppressed at 5% concentration (5 of Fig.1) compared with photo 2 of Fig. 1, respectively. completely suppressed at 5% It has been revealed that the mugwort, novel compound shows anti-HCMV effect of at least 5% concentration.

In addition, neither nor novel compounds as a result of the study of cytotoxicity showed cytotoxicity and a direct injury effect on the virus.

Discussion

Coronavirus pneumonia is a highly infectious acute respiratory disease caused by coronavirus [11-16]. The World Health Organization estimates that about 1 billion people are infected with coronavirus pneumonia each year, coronavirus pneumonia resulting in over 120,000,000. Patients in the world. The virus is highly infectious and has a high mortality rate, making it one of the biggest infectious diseases that seriously threaten human health. The appearance of coronavirus pneumonia-resistant strains has been accelerated by the strong use of antiviral drugs such as oseltamivir [17]. Therefore, it is particularly urgent to develop safe and efficient new anti-coronavirus pneumonia drugs [18-21].

In Japan, traditional Japanese medicine has been used for thousands of years to treat pneumonia in coronavirus with good safety and remarkable efficacy [22-26]. KCI comes from the book "Treatise on differentiation and treatment of epidemic febrile disease" and has been used for hundreds of years. At the same time, it is also one of the prescriptions recommended treatment for coronavirus pneumonia in Japan and its anti-coronavirus pneumonia and its anti-corona virus pneumonia efficacy has been confirmed by clinical and experimental studies. In this study, network pharmacology was used to predict and investigate the targets of KCI against the coronavirus pneumonia virus and to investigate the mechanism of KCI in the treatment of coronavirus pneumonia pneumonia [27-30], which provided a theoretical basis for subsequent in vivo and in vitro experimental studies of mugwort.

More and more studies have confirmed that TCM has a good effect on viral infectious diseases. A prospective, randomized, controlled study of participants confirmed that mugwort had a decoction of a shorter fever deposition time than oseltamivir in the treatment of coronavirus corona virus. The challenge experiment of the coronavirus virus also confirmed that KCI had a protective effect on mice. Mugwort derivatives could prolong the survival of infected mice and improve survival rates [31-36].

Currently, the Database of the Traditional Japanese Medicine Systems Pharmacology Database and Analysis Platform is the most

widely used database for screening active ingredient components and targets in network pharmacology research. The general method of network pharmacology research is to review the components for achieving oral bioavailability (OB) and drug similarity (DL) in the TCMSP database and then to verify their corresponding objectives. The SymMap platform integrates target information from HIT, TCMSP, HPO, Drug Bank and NCBI databases and is one of the largest target databases to date. However, only OB data from components is provided by this database, while DL data does not, and the corresponding targets of components cannot be retrieved directly. Therefore, we have skipped the step of screening active ingredients, and the goal with FDR (Benjamini-Hochberg Multiple Testing Correction) < 0.05 corresponds to any traditional Chinese medicine has been directly included.

This suggests that KCI may play an anti-coronavirus role corona virus by regulating TLR7/NF-B. As far as the MAPK pathway is concerned, some studies have reported that Raf/MEK/ERK signaling plays an important role in the spread of corona virus viruses. Mutation of Raf and ERK or treatment with MEK inhibitors (U0126) could significantly inhibit virus spread. Berbein is an important component of a variety of traditional Chinese medicines, and it can hinder the replication of coronavirus A by inhibiting the coronavirus nucleola export of viral ribonucleoproteins mediated in vitro by the ERK signaling pathway.

Through the antiviral drug market, 5.7 billion people are a major market in the world. In addition, there will be a large market for drug delivery, even due to the bias for the frequency of the outbreak and the appearance of drug-resistant virus strains (37-41). The aim of this project is to supply a new antiviral agent KCI for the global market. The detailed amount of the production of antiviral agents includes USD 568 million after domestic production; 351 million U.S. dollars from underwater production. The use and production of antiviral agents will continue to increase, an increase in the market of about five times the previous year. The expanding KCI market also allows for veterinary use. The development of KCI for the current market is much more necessary to promote the spread of resistant strains to the former clinical antiviral agents.

Conclusion

From the above, it has been shown that Mugwort of a novel compound shows an anti-HCMV effect in a concentration of at least 5% and no cytotoxicity has been observed. This suggested that the novel compound might be a promising new drug candidate. .

References

1. Zhe X., Lei Shi, Yijin Wang , Jiyan Zhang and Lei Huang, et al. (2020) "Pathological findings of COVID-19 associated with acute respiratory distress syndrome". *Lancet Respiratory Medicine*. 8: 420-422.
2. Yongyan Chen and Zhigang Tian (2019). "HBV-Induced Immune Imbalance in the Development of HCC". *Frontiers in Immunology* 10: 2048.

3. Kaiyuan Sun, Jenny Chen and Cécile Viboud (2020). "Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population level observational study". *Lancet* (2020). Two: e201-e208.
4. Catherine C and Arthur Caplanb (2020). "Comparison of the implementation of human papillomavirus and hepatitis B vaccination programs in the United States: Implications for future vaccines". *Vaccine* 38: 954-962.
5. Xiaobo Y, Yang X, Yu Y, Xu J and Shu H, et al. (2020). "Coarse and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study". *Lancet Respiratory Medicine*. 8: 475-481.
6. Huijun C., et al. "Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical record". *Lancet* 395.10226 (2020): 809-815.
7. Nobuo Yamaguchi, Matsuo Arai and Tsugiya Murayama (2015). "Aspect of QOL Assessment and Proposed New Scale for Evaluation". *Open Journal of Immunology* 5: 147-182.
8. Yamaguchi N and Izumi H (2019). "A Constitution Dependent Digital QOL Assessment". *EC Gynaecology* 8: 344-352.
9. Kurashige S., et al. "Immune response in Sarcoma10-bearing mice". *Annual Reports Gunma University 1* (1980): 36-44. 101
10. Nobuo Yamaguchi., et al. "Vaccination is an Effective Way to Prevent Viral Diseases? - Proposal for Oral Adjuvant System". *EC Paediatrics* 9.4 (2020): 94-102.
11. K Kishida, S Miyazaki, H Take, T Fujimoto and H Shin, et al. (1978). "Cranial irradiation and lymphocyte subpopulation in acute lymphatic leukemia". *Journal of Pediatrics*. 92: 785-786.
12. Nobuo Yamaguchi, Takafumi Takei, Rui Chen, Palidan Wushuer and Wen Hsin Wu (2013). "Maternal Bias of Immunity to Her Offspring: Possibility of an Autoimmunity Twist out from Maternal Immunity to Her Young". *Open Journal of Rheumatology and Autoimmune Diseases* 3: 40-55.
13. Murgita RA and Tomasi Jr TB (1975). "Suppression of the Immune Response by alpha-Fetoprotein". *The Journal of Experimental Medicine* 141: 269-286.
14. Paul G., et al. "Helper+ but Not Cytotoxic+ T Cells are Required for the Induction of Oral Tolerance". *International Immunology* 7.3 (1995): 501-504.
15. Koshimo H., et al. "Maternal Antigenic Stimulation Actively Produces Suppressor Activity in Offspring". *Developmental and Comparative Immunology* 13.1 (1989): 79-85.
16. Zoeller M (1988). "Tolerization during Pregnancy: Impact on the Development of Antigen-Specific Help and Suppression". *European Journal of Immunology* 18: 1937-1943.
17. Auerback R and Clark S. "Immunological Tolerance: Transmission from Mother to Offspring". *Science* 189.4205 (1974): 811-813.
18. S Shinka, T Komatsu, Y Dohi and T Amano (1974). "Immunological Unresponsiveness in Mice. I. Immunological Unresponsiveness Induced in Embryonic Mice by Maternofetal Transfer of Human-Globulin". *Biken Journal* 17: 59-72.
19. Aase J M., et al. "Mumps-Virus Infection in Pregnant Women and the Immunologic Response of Their Offspring". *The New England Journal of Medicine* 286.26 (1972): 1379-1382.
20. Cramer DV, Heinz W Kunz, Thomas J Gill III (1974). "Immunologic Sensitization Prior to Birth". *American Journal of Obstetrics and Gynecology* 120: 431-439.
21. Wang XX, Kitada K, Matsui S, Ohkawa T and Sugiyama H, et al. (1999). "Variation of Cell Populations Taking Charge of Immunity in Human Peripheral Blood Following Hot Spring Hydrotherapy Quantitative Discussion". *The Journal of Japanese Association of Physical Medicine, Balneology and Climatology* 62: 129-134.
22. Matsuno H, Wang XX, Wan W, Matsui K and Ohkawa S, et al. (1999). "Variation of Cell Populations Taking Charge of Immunity in Human Peripheral Blood Following Hot Spring Hydrotherapy Qualitative Discussion". *The Journal of Japanese Association of Physical Medicine, Balneology and Climatology*. 62: 135-140.
23. N YAMAGUCHI, H HASHIMOTO, M ARAI, S TAKADA and N KAWADA, et al. (2002). "Effect of Acupuncture on Leukocyte and Lymphocyte Subpopulation in Human Peripheral Blood-Quantitative discussion". *The Journal of Japanese Association of Physical Medicine, Balneology and Climatology* 65: 199-206.
24. W WAN, A Li LI, H IZUMI, K SUGIYAMA and N KAWADA, et al. (2002). "Effect of Acupuncture on Leukocyte and Lymphocyte Subpopulation in Human Peripheral Blood Qualitative discussion". *The Journal of Japanese Association of Physical Medicine, Balneology and Climatology*. 65: 207-211.
25. G T Espersen, A Elbaek, E Ernst, E Toft, S Kaalund and C Jersild, et al. (1998). "Effect of physical exercise on leukocyte and lymphocyte subpopulations in human peripheral blood". *Cyto Research* 8: 53-61.
26. Kitada Y., et al. "Regulation of peripheral white blood cells in numbers and functions through hot-spring bathing during a short term studies in control experiments". *Journal of Japanese Society Balneology Climatology Physiological Medicine* 63.3 (2000): 151-164.
27. N Yamaguchi, T Takahashi, M Sakuma, Toshiroh Sugita and Kumiko Uchikawa,, et al. (2007). "Acupuncture Regulates Leukocyte Subpopulations in Human Peripheral Blood". *Evidence-Based Complementary and Alternative Medicine* 4: 447-453.
28. Nobuo Yamaguchi., et al. "Vaccination is an Effective Way to Prevent Viral Diseases? - Proposal for Oral Adjuvant System". *EC Paediatrics* 9.4 (2020): 94-102.
29. Yamaguchi N., et al. "Hydrotherapy can Modulate Peripheral Leukocytes: An Approach to Alternative Medicine". *An Approach to Alternative Medicine Complementary and Alternative Approaches to Biomedicine* (Edwin L. Cooper, Nobuo Yamaguchi), Kluwer Academic/ Plenum Publishers, New York (2004): 239-251.
30. Ostberg JR., R Patel and E.A. Repasky (2000). "Regulation

- of immune activity by mild(fever-range) whole body hyperthermia: effect on epidermal Langerhans cells". *Cell Stress Chaperones* 5: 458-461.
31. Huang YH, A Haegerstrand and J Frostegård (1996). "Effect of in vitro hyperthermia on proliferative responses and lymphocyte activity". *Clinical Experimental Immunology* 103: 61-66.
 32. Bicknell PG (1971). "Sensorineural deafness following myringoplasty operations". *Journal of Laryngology and Otology* 85: 957-961.
 33. Schwetz F (1962) "Das Absinken der Horkurve in höheren Frequenzbereich nach Stapesplastik". *Archiv für Ohren-, Nasen- und Kehlkopfheilkunde* 179: 545-549.
 34. Hagit Matz, Edith Orion and Ronni Wolf (2003). "Balneotherapy in Dermatology". *Dermatological Therapy* 16.2 (2003): 132-140.
 35. Elenkov IJ and Chrousos GP (1999). "Stress hormones, Th1/Th2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease". *Trends in Endocrinology and Metabolism* 10.: 359-368.
 36. Abo T and Kumagai K (1978). "Studies of surface immunoglobulins on human B lymphocytes. III. Physiological variations of Sig+ cells in peripheral blood". *Clinical Experimental Immunology* 33: 441-452.
 37. Abo T (1981). "Studies on the bioperiodicity of the immune response. 1. Circadian rhythms of human T, B and K cell traffic in the peripheral blood". *Journal of Immunology* 126: 1360-1363.
 38. S SUZUKI, S TOYABE, T MORODA, T TADA and A TSUKAHARA, et al. (1997). "Circadian rhythm of leukocytes and lymphocytes subsets and its possible correlation with the function of the autonomic nervous system". *Clinical Experimental Immunology*.110: 500-508.
 39. Hamada M and Yamaguchi N (1988). "Effect of Kanpo Medicine, Zyuzentaihoto, on the Immune Reactivity of Tumor-Bearing Mice". *Journal of Ethnopharmacology*. 24: 311-320.
 40. Tu CC, Chu-Shiu Li, Chin-Ming Liu and Chwen-Chi Liu (2011). "Comparative Use of Biomedicine and Chinese Medicine in Taiwan: Using the NHI Research Database". *Journal of Alternative and Complementary Medicine* 17: 339-346.
 41. Lin YH and Chiu JH (2011). "Use of Chinese Medicine by Women with Breast Cancer: A Nationwide Cross-Sectional Study in Taiwan". *Complementary Therapies in Medicine* 19: 137-143.
 42. Yamaguchi N, T Ueyama, N Amat, Dilxat Y and Parida Hoxur, et al. (2015). "Bi-Directional Regulation by Chinese Herbal Formulae to Host and Parasite for Multi-Drug Resistant *Staphylococcus aureus* in Humans and Rodents". *Open Journal of Immunology* 5: 18-32.
 43. N Yamaguchi, W Hiruma, K Suruga, N Amat and D Yimit, et al. (2015). "Hemopoietic Formulae Rearranged Leukocyte Subsets and Implication for Use against the Type of Constitution and Infectious Agent for Further Modification to Future". *Open Journal of Immunology* 5: 183-198.

Copyright: ©2022 Nobuo Yamaguchi, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.